Alzamend Neuro Inc

NASDAQ: ALZN · Healthcare · Biotechnology

PublicHQ Atlanta, GA · FultonCIK 0001677077Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 28

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$4.5M

Employees

as of 2026-09-22

Market cap

$7.4M

as of 2026-09-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$4.5M-$4.5M2025

Operating income-$4.5M-$4.5M2025

Total assets$4.6M$4.6M2025

Liabilities$634.8k$634.8k2025

Equity$4.0M$4.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Alzamend Neuro Inc’s financial profile?

Alzamend Neuro Inc earned -$4.5M in FY2025 net income.

Peers · Healthcare

Skye Bioscience, Inc.——CNS Pharmaceuticals, Inc.——Apimeds Pharmaceuticals US, Inc——AI Maverick Intel, Inc.——Curative Biotechnology, Inc.——Reviva Pharmaceuticals Holdings, Inc.——

Neighbors

Fulton →

The Coca-Cola Company$47.9B82B+The Home Depot, Inc.$164.7B82B+The Southern Company$28.9B73B Intercontinental Exchange, Inc.$12.6B76B+United Parcel Service, Inc.$88.7B72B Norfolk Southern Corporation$12.2B81B+

Key facts

CEOStephan Jackman

SectorHealthcare

IndustryBiotechnology

HeadquartersAtlanta, GA

ExchangeNASDAQ: ALZN

Employees6

IPO date2021-06-15

Latest filings

10-Q2026-09-10 8-K2026-08-03 10-K2026-07-22 8-K2026-07-21 8-K2026-04-17 8-K2026-03-20 10-Q2026-03-11 8-K2026-03-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.